Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, Crohn’s disease, and many other inflammatory conditions. Rinvoq typically stays in your system for 2 to 3 days after your last dose. Rinvoq ...
Hosted on MSN
AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug
AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement for its drug Rinvoq for the treatment of adults with moderately to severely ...
The U.S. Food and Drug Administration on Tuesday approved AbbVie Inc.’s (NYSE:ABBV) Rinvoq (upadacitinib), 15 mg, once daily, for giant cell arteritis (GCA). GCA is an inflammation of blood vessels, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback